Dr. Edward Mills reports

LIR LIFE SCIENCES ANNOUNCES INITIATION OF PHASE 1 MACROMOLECULE-ENABLED TRANSDERMAL DELIVERY DEVELOPMENT WITH NEULAND LABORATORIES

Neuland Laboratories Ltd. has ordered the required raw materials and is preparing to initiate phase 1 of its macromolecule-enabled transdermal delivery development activities under the previously announced services agreement (see company news release dated Jan. 8, 2026) between Neuland and LIR Life Sciences Corp.

Phase 1 of the program involves the solid-phase synthesis, purification and analytical characterization of a highly active macromolecule delivery agent of relevance to LIR's transdermal delivery platform. Neuland will produce approximately 200 milligrams of an efficient transdermal agent as part of this initial development phase.

This phase 1 work represents the first operational step in a staged development program designed to support formulation development, transdermal testing and subsequent biological evaluation in collaboration with LIR's external research partners. The material generated in this phase is intended for early feasibility and performance studies rather than commercial use.

Neuland is a globally recognized pharmaceutical manufacturer with established expertise in chemical synthesis, analytical characterization and GMP-aligned (good manufacturing practice) development processes. Under the agreement, Neuland is responsible for executing the phase 1 synthesis in accordance with agreed technical specifications and industry standards, with all resulting materials and data owned by LIR.

The initiation of the macromolecule-enabled transdermal delivery development follows LIR's recent progress across multiple preclinical programs aimed at advancing needle-free, skin-applied delivery strategies for peptide-based therapies. Data generated from this work are expected to inform subsequent formulation optimization and selection of lead candidates for further development.

"This phase builds on the strong foundational work already completed and represents an important step in translating that progress into material for formulation and transdermal evaluation. Our work with Neuland is expected to add practical development insight around macromolecule production, formulation performance and the considerations that will help shape the next stages of our preclinical program," said Dr. Edward Mills, chief executive officer of LIR Life Sciences.

About LIR Life Sciences Corp.

LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.

We seek Safe Harbor.